Skip Navigation

Opinions

  • Print
  • Comment
  • | Share

Bringing biotechnologies from bench to bedside

Source: Nature

21 September 2007 | EN | 中文

AIDS vaccine in development

AIDS vaccine in development

European Communities

A model framework for taking health-related biotechnologies "from the lab to the village" is outlined in this Nature article by Peter Singer and colleagues.

They say it offers a guide to identifying factors that could impede the development of new products — such as vaccines, nutritionally enhanced foods, chemical and genetic strategies to control vectors and diagnostics — in developing countries.

In Africa, they say, it could provide a blueprint for commercialising African health products.

Based on interviews with 70 "key experts", they put potential bottlenecks into four categories — scientific, social, financial and political. In terms of science, participants highlighted scientific capacity, infrastructure and collaboration as important.

Collaboration can improve capacity, say the authors, but care must be taken to avoid potential conflicts or exploitation. Interviewees also stressed the need for care in ensuring that scientific experts are not poached from Southern countries.

Interviewees called for Southern governments to follow Brazil, China, India, Rwanda, South Africa and Thailand in giving priority to science and technology.

Link to full article in Nature

Add your comment

This is your network: share your views on any of our articles by adding your comments.

You need to be signed in to post a comment or to email a consenting comment author. Please sign in or sign up.

All comments are subject to approval and we reserve the right to edit comments containing inappropriate/unsuitable language. SciDev.Net holds copyright for all material posted on the website. Please see terms of use for further details.

All SciDev.Net material is free to reproduce providing that the source and author are appropriately credited. For further details see Creative Commons.

Back to Opinions
To the top